← Back to Search

CAR T-cell Therapy

Siremadlin for Acute Myeloid Leukemia

Phase 1 & 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- AML in first CR (CR1) prior to allo-SCT with one of the following:
-- Therapy-related AML (t-AML).
Must not have
Prior exposure to MDM-inhibitor
Active acute GvHD (aGvHD) of any grade (per Harris et al 2016) and/or active chronic GvHD (cGvHD ) of any grade (per NIH criteria (Jagasia et al 2015)) requiring systemic therapy at time of study treatment initiation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year and at 2 years after start of study treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug to prevent leukemia relapse in adult patients after stem cell transplant.

Who is the study for?
This trial is for adults with Acute Myeloid Leukemia (AML) who are in remission after a stem cell transplant but at high risk of relapse. They should be within 60-120 days post-transplant, have had certain genetic risks or therapy-related AML, and show no signs of hematologic relapse. Participants need good organ function and an adequate blood count.
What is being tested?
The study tests the safety and effectiveness of Siremadlin alone, and combined with donor lymphocyte infusion (DLI), in preventing AML relapse after transplantation. It aims to find the right dose and schedule for patients who've received transplants from matched donors.
What are the potential side effects?
While specific side effects for Siremadlin aren't listed here, common ones may include gastrointestinal issues like nausea or diarrhea, potential liver or kidney problems indicated by lab tests, as well as possible immune system reactions due to DLI.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have a specific type of leukemia that developed as a result of a previous bone marrow disorder or blood cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
You currently have a type of graft-vs-host disease called acute or chronic GvHD that requires treatment.
Select...
You had a stem cell or cord blood transplant with a donor who is not a full match with you.
Select...
You have digestive problems like severe diarrhea, uncontrollable nausea or vomiting, or GI bleeding that may prevent you from taking and absorbing oral siremadlin.
Select...
You cannot take medication that increases the activity of a certain enzyme (CYP3A) 14 days before or during the study.
Select...
You have a significant heart condition or abnormal heart rhythm.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year and at 2 years after start of study treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year and at 2 years after start of study treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mutagenicity Tests
Percentage of participants who are alive and maintained complete remission (CR) or complete response with incomplete hematological recovery (CRi) with no evidence of hematologic relapse
Time to Dose Limiting Toxicity (DLT) with siremadlin in combination with Donor Lymphocyte Infusion (DLI), in part 2
Secondary study objectives
Cumulative incidence of AML relapse
Incidence of Graft versus Host Disease (GvHD)
PK characteristic Cmax of siremadlin
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Siremadlin (HDM201)Experimental Treatment1 Intervention
Participants with AML post allogeneic stem cell transplantation (allo-SCT) will receive siremadlin monotherapy in part 1 and siremadlin monotherapy as well as in combination with donor lymphocyte infusion in part 2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Siremadlin
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,920 Previous Clinical Trials
4,254,294 Total Patients Enrolled

Media Library

Siremadlin (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05447663 — Phase 1 & 2
Stem Cell Transplant Research Study Groups: Siremadlin (HDM201)
Stem Cell Transplant Clinical Trial 2023: Siremadlin Highlights & Side Effects. Trial Name: NCT05447663 — Phase 1 & 2
Siremadlin (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05447663 — Phase 1 & 2
~3 spots leftby Dec 2025